226 related articles for article (PubMed ID: 35366855)
21. Hepatitis C Virus Infection Is Inhibited by a Noncanonical Antiviral Signaling Pathway Targeted by NS3-NS4A.
Vazquez C; Tan CY; Horner SM
J Virol; 2019 Dec; 93(23):. PubMed ID: 31534039
[TBL] [Abstract][Full Text] [Related]
22. Sequence analysis of NS3 protease gene in clinical strains of hepatitis C virus.
Lodrini S; Bagaglio S; Canducci F; De Mitri MS; Andreone P; Loggi E; Lazzarin A; Clementi M; Morsica G
J Biol Regul Homeost Agents; 2003; 17(2):198-204. PubMed ID: 14518724
[TBL] [Abstract][Full Text] [Related]
23. Modulation of hepatitis C virus NS3 protease and helicase activities through the interaction with NS4A.
Gallinari P; Paolini C; Brennan D; Nardi C; Steinkühler C; De Francesco R
Biochemistry; 1999 Apr; 38(17):5620-32. PubMed ID: 10220351
[TBL] [Abstract][Full Text] [Related]
24. Differential efficacy of protease inhibitors against HCV genotypes 2a, 3a, 5a, and 6a NS3/4A protease recombinant viruses.
Gottwein JM; Scheel TK; Jensen TB; Ghanem L; Bukh J
Gastroenterology; 2011 Sep; 141(3):1067-79. PubMed ID: 21699793
[TBL] [Abstract][Full Text] [Related]
25. Establishment of an in vitro assay system for screening hepatitis C virus protease inhibitors using high performance liquid chromatography.
Sudo K; Inoue H; Shimizu Y; Yamaji K; Konno K; Shigeta S; Kaneko T; Yokota T; Shimotohno K
Antiviral Res; 1996 Aug; 32(1):9-18. PubMed ID: 8863991
[TBL] [Abstract][Full Text] [Related]
26. Comparative molecular dynamics simulation of Hepatitis C Virus NS3/4A protease (Genotypes 1b, 3a and 4b) predicts conformational instability of the catalytic triad in drug resistant strains.
Kramer M; Halleran D; Rahman M; Iqbal M; Anwar MI; Sabet S; Ackad E; Yousef MS
PLoS One; 2014; 9(8):e104425. PubMed ID: 25111232
[TBL] [Abstract][Full Text] [Related]
27. Identification of the sequence on NS4A required for enhanced cleavage of the NS5A/5B site by hepatitis C virus NS3 protease.
Shimizu Y; Yamaji K; Masuho Y; Yokota T; Inoue H; Sudo K; Satoh S; Shimotohno K
J Virol; 1996 Jan; 70(1):127-32. PubMed ID: 8523516
[TBL] [Abstract][Full Text] [Related]
28. Multiple enzymatic activities associated with recombinant NS3 protein of hepatitis C virus.
Gallinari P; Brennan D; Nardi C; Brunetti M; Tomei L; Steinkühler C; De Francesco R
J Virol; 1998 Aug; 72(8):6758-69. PubMed ID: 9658124
[TBL] [Abstract][Full Text] [Related]
29. Identification of novel small molecule inhibitors against the NS3/4A protease of hepatitis C virus genotype 4a.
El-Sayed SM; Ali MAM; El-Gendy BEM; Dandash SS; Issac Y; Saad R; Azab MM; Mohamed MR
Curr Pharm Des; 2018; 24(37):4484-4491. PubMed ID: 30501598
[TBL] [Abstract][Full Text] [Related]
30. Protease and helicase activities of hepatitis C virus genotype 4, 5, and 6 NS3-NS4A proteins.
Massariol MJ; Zhao S; Marquis M; Thibeault D; White PW
Biochem Biophys Res Commun; 2010 Jan; 391(1):692-7. PubMed ID: 19944069
[TBL] [Abstract][Full Text] [Related]
31. The conformation of hepatitis C virus NS3 proteinase with and without NS4A: a structural basis for the activation of the enzyme by its cofactor.
Love RA; Parge HE; Wickersham JA; Hostomsky Z; Habuka N; Moomaw EW; Adachi T; Margosiak S; Dagostino E; Hostomska Z
Clin Diagn Virol; 1998 Jul; 10(2-3):151-6. PubMed ID: 9741640
[TBL] [Abstract][Full Text] [Related]
32. Portulaca oleracea L. as a Prospective Candidate Inhibitor of Hepatitis C Virus NS3 Serine Protease.
Noreen S; Hussain I; Tariq MI; Ijaz B; Iqbal S; Qamar-ul-Zaman ; Ashfaq UA; Husnain T
Viral Immunol; 2015 Jun; 28(5):282-9. PubMed ID: 25871297
[TBL] [Abstract][Full Text] [Related]
33. How to find simple and accurate rules for viral protease cleavage specificities.
Rögnvaldsson T; Etchells TA; You L; Garwicz D; Jarman I; Lisboa PJ
BMC Bioinformatics; 2009 May; 10():149. PubMed ID: 19445713
[TBL] [Abstract][Full Text] [Related]
34. Zika virus NS4A N-Terminal region (1-48) acts as a cofactor for inducing NTPase activity of NS3 helicase but not NS3 protease.
Kumar D; Kumar A; Bhardwaj T; Giri R
Arch Biochem Biophys; 2020 Nov; 695():108631. PubMed ID: 33080173
[TBL] [Abstract][Full Text] [Related]
35. Enzymatic characterization of membrane-associated hepatitis C virus NS3-4A heterocomplex serine protease activity expressed in human cells.
Hamill P; Jean F
Biochemistry; 2005 May; 44(17):6586-96. PubMed ID: 15850392
[TBL] [Abstract][Full Text] [Related]
36. Development and application of a fast, reproducible assay to measure HCV NS3 protease activity using Escherichia coli lysate.
Han B; Dvory-Sobol H; Greenstein A; McCarville JF; Hung M; Liu X; Miller MD; Mo H
J Virol Methods; 2015 Dec; 225():76-86. PubMed ID: 26391876
[TBL] [Abstract][Full Text] [Related]
37. Enhancement of hepatitis C virus NS3 proteinase activity by association with NS4A-specific synthetic peptides: identification of sequence and critical residues of NS4A for the cofactor activity.
Butkiewicz NJ; Wendel M; Zhang R; Jubin R; Pichardo J; Smith EB; Hart AM; Ingram R; Durkin J; Mui PW; Murray MG; Ramanathan L; Dasmahapatra B
Virology; 1996 Nov; 225(2):328-38. PubMed ID: 8918919
[TBL] [Abstract][Full Text] [Related]
38. Hepatitis C virus NS3/4A protease.
Kwong AD; Kim JL; Rao G; Lipovsek D; Raybuck SA
Antiviral Res; 1999 Feb; 41(1):67-84. PubMed ID: 10321580
[TBL] [Abstract][Full Text] [Related]
39. Exploring small molecules with pan-genotypic inhibitory activities against hepatitis C virus NS3/4A serine protease.
Ren J; Ojeda I; Patel M; Johnson ME; Lee H
Bioorg Med Chem Lett; 2019 Aug; 29(16):2349-2353. PubMed ID: 31201062
[TBL] [Abstract][Full Text] [Related]
40. Establishment of a cell-based assay system for hepatitis C virus serine protease and its primary applications.
Mao HX; Lan SY; Hu YW; Xiang L; Yuan ZH
World J Gastroenterol; 2003 Nov; 9(11):2474-9. PubMed ID: 14606079
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
